TherapeuticsMD, Inc. Income (Loss) from Continuing Operations, Per Diluted Share
TherapeuticsMD, Inc. (TXMD) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.01 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-08-11
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was $0.01, a 80.00% decline year-over-year.
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-03-31 was $0.01.
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was $0.00.
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was $0.05.
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$0.06.
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$0.20.
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$0.74, a 772.73% decline from fiscal 2022.
- TherapeuticsMD, Inc. income (loss) from continuing operations, per diluted share for fiscal 2022 was $0.11.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.01 10-Q · filed 2026-08-11 | $0.02 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $0.01 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$0.06 10-K/A · filed 2026-04-01 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $0.05 10-Q · filed 2026-08-11 | -$0.01 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | -$0.06 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$0.20 10-K/A · filed 2026-04-01 | |||
| 2024-09-30 | -$0.05 10-Q · filed 2025-11-12 | -$0.21 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | -$0.09 10-Q · filed 2025-08-12 | -$0.16 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$0.07 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$0.74 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$0.13 10-Q · filed 2023-11-14 | -$0.60 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | -$0.24 10-Q · filed 2024-08-12 | -$0.47 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$0.24 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $0.11 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$1.58 10-Q · filed 2023-11-14 | -$5.34 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$1.70 10-Q · filed 2023-08-14 | -$3.77 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$2.08 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$9.96 10-K · filed 2023-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |